benzyl (2E)-2-[(3S)-3-[(1R)-1-[tert-butyl(dimethyl)silyl]oxyethyl]-4-oxoazetidin-2-ylidene]acetate | 868082-97-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl (2E)-2-[(3S)-3-[(1R)-1-[tert-butyl(dimethyl)silyl]oxyethyl]-4-oxoazetidin-2-ylidene]acetate
• CAS: 868082-97-7
• 化学式: C₂₀H₂₉NO₄Si
• 分子量: 375.54
• InChiKey: COCMXHGKPIHRBM-AWWQTPIYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.77
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  benzyl (2E)-2-[(3S)-3-[(1R)-1-[tert-butyl(dimethyl)silyl]oxyethyl]-4-oxoazetidin-2-ylidene]acetate 在 palladium on activated charcoal 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 丙酮 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  4-Alkyliden-β-lactams conjugated to polyphenols: Synthesis and inhibitory activity

  摘要：

  A series of compounds combining the beta-lactain and polyphenol scaffold have been prepared and evaluated for inhibition of human leukocyte elastase and matrix metallo-proteases MMP-2 and MMP-9. The design of these compounds has been based on the 'overlapping-type' strategy where two pharmacophores are linked in a single molecule. The most powerful compound against elastase was an N-galloyl-4-alkyliden beta-lactam, [3-[1-(tert-butyl-dimethyl-silanyloxy)-ethyl]-4-oxo-1-(3,4,5-tris-benzyloxy-benzoyl)-azetidin-2-ylidene]-acetic acid ethylester, with an IC50 of 0.5 mu M; while the most powerful against MMP-2 was a 4-alkyliden beta-lactam arylated on the C-3 hydroxy side chain (3,5-bis-benzyloxy-4-hydroxy-benzoic acid 1-(2-benzyloxycarbonylmethylene4-oxo-azetidin-3-yl)-ethyl ester) with an IC50 of 4 mu M. Of the total 35 compounds tested, high levels of inhibition of elastase and of MMPs were separately exerted by distinct molecules. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.06.041
• 作为产物：
  描述：

  3-(2-tert-butyldimethylsilyloxyethyl)-4-acetoxy-azetidin-2-one 、 benzyl diazoacetate 在 四氯化钛 作用下， 以 二氯甲烷 为溶剂， 以54%的产率得到benzyl (2Z)-2-[(3S)-3-[(1R)-1-[tert-butyl(dimethyl)silyl]oxyethyl]-4-oxoazetidin-2-ylidene]acetate
  参考文献：
  名称：

  4-亚烷基-β-内酰胺的设计，合成和生物学评估：对抗药性细菌具有有前途的抗生素活性的新产品。

  摘要：

  据报道4-亚烷基-氮杂环丁烷-2-酮作为新型抗多药耐药病原体的抗菌剂的设计，合成和抗菌活性。从4-乙酰氧基-氮杂环丁烷酮和重氮酯开始，可以使用原始方案轻松获得4-炔基-氮杂环丁烷-2-酮。进一步详细阐述了母体化合物，以获得一个小型的4-亚烷基衍生物库。使用基于VRS概念的GRID描述符的分子建模方法可识别出有吸引力的药物候选物，并有助于QSAR中官能团效应的合理化。通过确定其最低抑菌浓度（MIC），评估了新药对43种近期对抗生素敏感和耐药的革兰氏阳性和革兰氏阴性病原体临床分离株的体外抗菌活性。活性最高的化合物对某些测试细菌的MIC值为0.25至32 mg / L。有趣的是，一些化合物对金黄色葡萄球菌对甲氧西林敏感和耐药的菌株表现出相似的活性，表明这些试剂的可能替代作用机制是由细胞毒性和初步扫描电子显微镜研究支持的。

  DOI：

  10.1021/jm0580510

文献信息

• Antibacterial Agents and Cystic Fibrosis: Synthesis and Antimicrobial Evaluation of a Series of N-Thiomethylazetidinones
  作者：Paola Galletti、Clementina E. A. Cocuzza、Matteo Pori、Arianna Quintavalla、Rosario Musumeci、Daria Giacomini

  DOI：10.1002/cmdc.201100282

  日期：2011.10.4

  challenges in the clinical management of infectious disease. New antimicrobial agents are therefore urgently required, particularly in the treatment of chronic and recurrent infections often associated with antibiotic‐resistant pathogens, as in the case of cystic fibrosis (CF) patients. This study reports the antibacterial activity of a series of monocyclic β‐lactams with an alkylidenecarboxyl chain or

  多药耐药性微生物的日益增多是传染病临床管理中的最大挑战之一。因此，迫切需要新的抗菌剂，尤其是在治疗经常与抗生素耐药性病原体相关的慢性和复发感染时，例如在囊性纤维化（CF）患者的情况下。这项研究报告了一系列在环的C4位带有亚烷基羧基链或吸电子基团（例如4-OAc，4-SAc和4-SO 2 Ph）的单环β-内酰胺的抗菌活性。比较了N-未取代和N-硫代甲基衍生物。总共测试了33种氮杂环丁酮对革兰氏阳性和革兰氏阴性细菌临床分离株的活性。一个组合发现N-硫代甲基和4-亚烷基侧链上的苄基酯可增强革兰氏阳性菌的效力。相对于相应的NH衍生物，N-硫甲基明显提高了4-乙酰氧基氮杂环丁酮的活性。活性最高的化合物对从CF患儿中分离出的耐甲氧西林金黄色葡萄球菌的最低抑菌浓度（MIC）值分别为4和8 mg L -1。
• 4-Alkyliden-β-lactams conjugated to polyphenols: Synthesis and inhibitory activity
  作者：Gianfranco Cainelli、Paola Galletti、Spiridione Garbisa、Daria Giacomini、Luigi Sartor、Arianna Quintavalla

  DOI：10.1016/j.bmc.2005.06.041

  日期：2005.11

  A series of compounds combining the beta-lactain and polyphenol scaffold have been prepared and evaluated for inhibition of human leukocyte elastase and matrix metallo-proteases MMP-2 and MMP-9. The design of these compounds has been based on the 'overlapping-type' strategy where two pharmacophores are linked in a single molecule. The most powerful compound against elastase was an N-galloyl-4-alkyliden beta-lactam, [3-[1-(tert-butyl-dimethyl-silanyloxy)-ethyl]-4-oxo-1-(3,4,5-tris-benzyloxy-benzoyl)-azetidin-2-ylidene]-acetic acid ethylester, with an IC50 of 0.5 mu M; while the most powerful against MMP-2 was a 4-alkyliden beta-lactam arylated on the C-3 hydroxy side chain (3,5-bis-benzyloxy-4-hydroxy-benzoic acid 1-(2-benzyloxycarbonylmethylene4-oxo-azetidin-3-yl)-ethyl ester) with an IC50 of 4 mu M. Of the total 35 compounds tested, high levels of inhibition of elastase and of MMPs were separately exerted by distinct molecules. (c) 2005 Elsevier Ltd. All rights reserved.
• Design, Synthesis, and Biological Evaluation of 4-Alkyliden-beta Lactams:  New Products with Promising Antibiotic Activity Against Resistant Bacteria
  作者：Francesco Broccolo、Gianfranco Cainelli、Gianluigi Caltabiano、Clementina E. A. Cocuzza、Cosimo G. Fortuna、Paola Galletti、Daria Giacomini、Giuseppe Musumarra、Rosario Musumeci、Arianna Quintavalla

  DOI：10.1021/jm0580510

  日期：2006.5.1

  The design, synthesis, and antibacterial activity of 4-alkyliden-azetidin-2-ones as new antimicrobial agents against multidrug-resistant pathogens is reported. 4-Alkyliden-azetidin-2-ones were easily obtained using an original protocol starting from 4-acetoxy-azetidinones and diazoesters. Parent compounds were further elaborated to obtain a small library of 4-alkylidene derivatives. A molecular modeling

  据报道4-亚烷基-氮杂环丁烷-2-酮作为新型抗多药耐药病原体的抗菌剂的设计，合成和抗菌活性。从4-乙酰氧基-氮杂环丁烷酮和重氮酯开始，可以使用原始方案轻松获得4-炔基-氮杂环丁烷-2-酮。进一步详细阐述了母体化合物，以获得一个小型的4-亚烷基衍生物库。使用基于VRS概念的GRID描述符的分子建模方法可识别出有吸引力的药物候选物，并有助于QSAR中官能团效应的合理化。通过确定其最低抑菌浓度（MIC），评估了新药对43种近期对抗生素敏感和耐药的革兰氏阳性和革兰氏阴性病原体临床分离株的体外抗菌活性。活性最高的化合物对某些测试细菌的MIC值为0.25至32 mg / L。有趣的是，一些化合物对金黄色葡萄球菌对甲氧西林敏感和耐药的菌株表现出相似的活性，表明这些试剂的可能替代作用机制是由细胞毒性和初步扫描电子显微镜研究支持的。